News archive
Showing 654 results
September 2016
-
Media Release
Novartis BAF312 reduced the risk of disability progression in pivotal phase III study in secondary progressive MS patients
-- EXPAND study data presented at ECTRIMS 2016 show that treatment with BAF312 (siponimod) reduced the risk of three-month confirmed disability progression by 21% vs. placebo in patients with… -
Media Release
Novartis BAF312 reduced the risk of disability progression in pivotal phase III study in secondary progressive MS patients
-
Media Release
Novartis data finds relapsing MS patients on Gilenya® had greater treatment retention and satisfaction rates vs. injectable DMTs
- In a well-controlled, randomized, open-label study, Gilenya patients had higher treatment retention rates at one year, 81.3% vs. those on injectable DMTs, 29.2% - Throughout the study almost 10… -
Media Release
Novartis data finds relapsing MS patients on Gilenya® had greater treatment retention and satisfaction rates vs. injectable DMTs
July 2016
-
Media Release
Novartis announces FDA approval of Xolair® (omalizumab) for pediatric allergic asthma
-- Extension of indication makes Xolair the first and only approved biologic for pediatric patients six years and older with uncontrolled moderate to severe persistent allergic asthma-- Asthma is one… -
Media Release
Novartis announces FDA approval of Xolair® (omalizumab) for pediatric allergic asthma
June 2016
-
Media Release
Largest global psoriasis survey shows 85% of U.S. respondents faced social stigma like discrimination and humiliation because of their skin
- Global survey, including more than 1,400 U.S. moderate-to-severe psoriasis patients, is the first to look at perceptions of clear skin1- Despite the significant impact of living with the disease,… -
Media Release
Largest global psoriasis survey shows 85% of U.S. respondents faced social stigma like discrimination and humiliation because of their skin
-
Media Release
Timely use of Novartis' Entresto could prevent or postpone over 28,000 US deaths per year among HFrEF patients, according to an expert analysis in JAMA Cardiology
Findings are first to quantify magnitude of potential survival benefits if Entresto were prescribed to all eligible US HFrEF patients (as defined by authors)(1)Cardiology experts highlight risk of… -
Media Release
Timely use of Novartis' Entresto could prevent or postpone over 28,000 US deaths per year among HFrEF patients, according to an expert analysis in JAMA Cardiology
-
Media Release
Novartis data show Gilenya® had significantly greater patient retention compared to iDMTs in relapsing-remitting MS
- Data demonstrate at 12 months, 81% of patients started on fingolimod stay on therapy vs. 29% started on injectable disease-modifying therapies (iDMTs)(1)- Injectable disease-modifying therapies are… -
Media Release
Novartis data show Gilenya® had significantly greater patient retention compared to iDMTs in relapsing-remitting MS